Cutaneous T-cell lymphoma (CTCL) represents a spectrum of diseases composed of malignant T lymphocytes. The most common type is mycosis fungoides (MF). An accurate diagnosis of early MF may be difficult because of the varied clinical and histologic expressions of the disease.
Methods
The authors review the epidemiology, possible risk factors, clinical manifestations, diagnostic techniques, staging, prognosis, and treatment options for MF.
Results
The varied and often nonspecific clinical and bistologic presentations of MF may delay diagnosis and staging, thus necessitating further studies such as immunophenotyping and T-cell receptor gene rearrangement analysis.
Conclusions
A multidisciplinary approach to the diagnosis, staging, and treatment of MF assists in optimizing outcomes from management of patients with this disease.
References
1.
WillemzeR., JaffeE.S., BurgG.. WHO-EORTC classification for cutaneous lymphomas.Blood.2005; 105: 3768–3785. Epub 2005 Feb 3.
2.
KimE.J., LinJ., Junkins-HopkinsJ.M.. Mycosis fungoides and Sezary syndrome: an update.Curr Oncol Rep.2006; 8: 376–386.
3.
TrautingerF., KnoblerR., WillemzeR.. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome.Eur J Cancer.2006; 42: 1014–1030. Epub 2006 Mar 30.
4.
WhittakerS.. Biologic insights into the pathogenesis of cutaneous T-cell lymphoma (CTCL).Semin Oncol.2006; 33: S3–S6.
5.
WillemzeR., MeijerC.J.. Classification of cutaneous T-cell lymphoma: from ALibert to WHO-EORTC.J Cutan Pathol.2006; 33(Suppl 1): 18–26.
6.
VonderheidE.C.. On the diagnosis of erythrodermic cutaneous T-cell lymphoma.J Cutan Pathol2006; 33(Suppl 1): 27–42.
7.
van DoornR., van HaselenC.W., van Voorst VaderP.C.. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.Arch Dermatol.2000; 136: 504–510.
8.
ZackheimH.S., AminS., Kashani-SabetM.. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients.J Am Acad Dermatol.1999; 40: 418–425.
9.
KimY.H., LiuH.L., Mraz-GernhardS.. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.Arch Dermatol.2003; 139: 857–866.
10.
WainE.M., OrchardG.E., WhittakerS.J.. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study.Cancer.2003; 98: 2282–2290.
KohH.K., CharifM., WeinstockM.A.. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma.Hematol Oncol Clin North Am.1995; 9: 943–960.
13.
AlibertJ.L.M.. Description des Maladies de la Peau Observees a l'HopitalSt. Louis.: Barrois L'aine et Fils.1806: 413–446.
14.
WhittemoreA.S., HollyE.A., LeeI.M.. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study.J Natl Cancer Inst.1989; 81: 1560–1567.
15.
TuypE., BurgoyneA., AitchisonT.. A case-control study of possible causative factors in mycosis fungoides.Arch Dermatol.1987; 123: 196–200.
DiamandidouE., CohenP.R., KurzrockR.. Mycosis fungoides and Sezary syndrome.Blood.1996; 88: 2385–2409.
18.
TanR.S., ButterworthC.M., McLaughlinH.. Mycosis fungoides: a disease of antigen persistence.Br J Dermatol.1974; 91: 607–616.
19.
WantzinG.L., ThomsenK., NissenN.I.. Occurrence of human T cell lymphotropic virus (type 1) antibodies in cutaneous T cell lymphoma.J Am Acad Dermatol.1986; 15: 598–602.
20.
Munoz-PerezM.A., Rios-MartinJ.J., Rodriguez-PichardoA.. Cutaneous T-cell lymphoma and human immunodeficiency virus infection: 2 cases and a review of the literature.Acta Derm Venereol.1999; 79: 153–155.
21.
DrenoB., CelerierP., FleischmannM.. Presence of Epstein-Barr virus in cutaneous lesions of mycosis fungoides and Sezary syndrome.Acta Derm Venereol.1994: 74: 355–357.
22.
HerneK.L., TalpurR., Breuer-McHamJ.. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome.Blood.2003; 101: 2132–2136. Epub 2002 Nov 21.
23.
ErkekE., SenturkN., DincerI.. Identification of herpes simplex virus DNA and lack of human herpesevirus-8 DNA in mycosis fungoides.Acta Derm Venerol.2002; 82: 214–216.
24.
PancakeB.A., Zucker-FranklinD., CoutavasE.E.. The cutaneous T-cell lymphoma, mycosis fungoides, is a human T-cell lymphotropic virus-associated disease. A study of 50 patients.J Clin Invest.1995; 95: 547–554.
25.
Zucker-FranklinD., PancakeB.A.. The role of human T-cell lym-photropic viruses (HTLV-I and II) in cutaneous T-cell lymphomas.Semin Dermatol.1994; 13: 160–165.
LeeP.Y., CharleyM., TharpM.. Possible role of Epstein-Barr virus infection in cutaneous T-cell lymphomas.J Invest Dermatol.1990; 95: 309–312.
28.
JonesJ.F., ShurinS., AbramowskyC.. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections.N Engl J Med.1988; 318: 733–741.
29.
GirardiM., HealdP.W., WilsonL.D.. The pathogenesis of mycosis fun-goides.N Engl J Med.2004; 350: 1978–1988.
30.
WeinstockM.A.. Epidemiology of mycosis fungoides.Semin Dermatol.1994; 13: 154–159.
31.
MyskowskiP.L.. Cutaneous T-cell lymphoma and human immunodeficiency virus. The spectrum broadens.Arch Dermatol.1991; 127: 1045–1047.
32.
PascualJ., TorreloA., TeruelJ.L.. Cutaneous T cell lymphomas after renal transplantation.Transplantation.1992; 53: 1143–1145.
33.
KaufmanD., GordonL.I., VariakojisD.. Successfully treated Hodgkin's disease followed by mycosis fungoides: case report and review of the literature.Cutis.1987; 39: 291–296.
34.
TokuraY., HealdP.W., YanS.L.. Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins.J Invest Dermatol.1992; 98: 33–37.
35.
JackowC.M., CatherJ.C., HearneV.. Association of erythroder-mic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion.Blood.1997; 89: 32–40.
36.
AbramsJ.T., VonderheidE.C., KolbeS.. Sezary T-cell activating factor is a chlamydia pneumoniae-associated protein.Clin Diagn Lab Immunol.1999; 6: 895–905.
37.
BazinP.A.E.. Maladies de la Peau Observees a l'HopitalSt. Louis.Barrois L'aine et Fils. 1876.
38.
VidelE., BrocqL.. Etude sur le mycosis fungoides.Fr Med.1885; 14: 518–530.
39.
O'QuinnR.P., ZicJ.A., BoydA.S.. Mycosis fungoides d'emblee: CD30-negative cutaneous large T-cell lymphoma.J Am Acad Dermatol.2000; 43 (5 pt 1): 861–863.
40.
GuptaI.M., GuptaO.P., SamantH.C.. D'emblee type of mycosis fungoides of the head and neck.Laryngoscope.1975; 85: 898–903.
41.
BlasikL.G., NewkirkR.E., DimondR.L.. Mycosis fungoides d'emblee: a rare presentation of cutaneous T-cell lymphoma.Cancer.1982; 49: 742–747.
42.
LambrozaE., CohenS.R., PhelpsR.. Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases.J Am Acad Dermatol.1995; 32: 987–993.
BurgG., DummerR.. Small plaque (digitate) parapsoriasis is an ‘abortive cutaneous T-cell lymphoma’ and is not mycosis fungoides.Arch Dermatol.1995; 131: 336–338.
45.
AckermanA.B.. If small plaque (digitate) parapsoriasis is a cutaneous T-cell lymphoma, even an ‘abortive’ one, it must be mycosis fungoides!Arch Dermatol.1996; 132: 562–566.
46.
KurbanR.S., SafaiB.. Cutaneous T-cell lymphomas. In: Cancer of the Skin.Philadelphia, Pa: WB Saunders Co; 1991.
47.
DMitrovskyE., MatthewsM.J., BunnP.A.. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.J Clin Oncol.1987; 5: 208–215.
48.
GreerJ.P., SalhanyK.E., CousarJ.B.. Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process.Hematol Oncol.1990; 8: 215–227.
49.
CerroniL., RiegerE., HodlS.. Clinicopathologic and immunolog-ic features associated with transformation of mycosis fungoides to large-cell lymphoma.Am J Surg Pathol.1992; 16: 543–552.
50.
KerlH., HodlS., SmolleJ.. Classification and prognosis of cutaneous T-cell lymphomas [In German].Z Hautkr.1986; 61: 63–67.
51.
DiamandidouE., Colome-GrimmerM., FayedL.. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.Blood.1998; 92: 1150–1159.
52.
VergierB., de MuretA., Beylot-BarryM.. Transformation of mycosis fungoides: clinicopathological features and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas.Blood.2000; 95: 2212–2218.
53.
HowardM.S., SmollerB.R.. Mycosis fungoides: classic disease and variant presentations.Semin Cutan Med Surg.2000; 19: 91–99.
54.
FlaigM.J., CerroniL., SchuhmannK.. Follicular mycosis fun-goides. A histopathologic analysis of nine cases.J Cutan Pathol.2001; 28: 525–530.
55.
KeM.S., KamathN.V., NihalM.. Folliculotropic mycosis fungoides with central nervous system involvement: demonstration of tumor clonality in intrafollicular T cells using laser capture microdissection.J Am Acad Der-matol.2003; 48: 238–243.
56.
van DoornR., SchefferE., WillemzeR.. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients.Arch Dermatol.2001; 138: 191–198.
57.
HaghighiB., SmollerB.R., LeBoitP.E.. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinico-pathologic study.Mod Pathol.2000; 13: 502–510.
van HaselenC.W., ToonstraJ., van der PutteS.J.. Granulomatous slack skin. Report of three patients with an updated review of the literature.Dermatology.1998; 196: 382–391.
61.
ClarijsM., PootF., LakaA.. Granulomatous slack skin: treatment with extensive surgery and review of the literature.Dermatology.2003; 206: 393–397.
62.
EdelsonR.L.. Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants.J Am Acad Dermatol.1980; 2: 89–106.
63.
WeinstockM.A., HormJ.W.. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides.Cancer.1988; 62: 1658–1661.
VonderheidE.C., BernengoM.G., BurgG.. Update on erythroder-mic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.J Am Acad Dermatol.2002; 46: 95–106.
66.
WinkelmannR.K., BuechnerS.A., Diaz-PerezJ.L.. Pre-Sezary syndrome.J Am Acad Dermatol.1984; 10: 992–999.
HealdP., YanS.L., EdelsonR.. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma.Arch Dermatol.1994; 130: 198–203.
69.
WieselthierJ.S., KohH.K.. Sezary syndrome: diagnosis, prognosis, and critical review of treatment options.J Am Acad Dermatol.1990; 22: 381–401.
70.
BravermanI.M., YagerN.B., ChenM.. Combined total body electron beam irradiation and chemotherapy for mycosis fungoides.J Am Acad Dermatol.1987; 16: 45–60.
71.
GlusacE.J.. Criterion by criterion, mycosis fungoides.Am J Der-matopathol.2003; 25: 264–269.
72.
BignonY.J., RogerH., SouteyrandP.. Study of T-cell antigen receptor gene rearrangement: a useful tool for early diagnosis of mycosis fungoides.Acta Derm Venereol.1989; 69: 217–222.
73.
BergerC.L., EisenbergA., SoperL.. Dual genotype in cutaneous T cell lymphoma: immunoglobulin gene rearrangement in clonal T cell malignancy.J Invest Dermatol.1988; 90: 73–77.
74.
WeissL.M., WoodG.S., TrelaM.. Clonal T-cell populations in lym-phomatoid papulosis. Evidence of a lymphoproliferative origin for a clinically benign disease.N Engl J Med.1986; 315: 475–479.
75.
BunnP.A.Jr, LambergS.I.. Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas.Cancer Treat Rep.1979; 63: 725–728.
76.
SausvilleE.A., EddyJ.L., MakuchR.W.. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups.Ann Intern Med.1988; 109: 372–382.
77.
SchmidM.H., BirdP., DummerR.. Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept.Arch Dermatol.1999; 135: 1204–1208.
78.
SausvilleE.A., WorshamG.F., MatthewsM.J.. Histologic assessment of lymph nodes in mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system.Hum Pathol.1985; 16: 1098–1109.
79.
DummerR., KempfW., Hess SchmidM.. Therapy of cutaneous lymphoma — current practice and future developments.Onkologie.2003; 26: 366–372.
80.
BekkenkM.W., GeelenF.A., van Voorst VaderP.C.. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.Blood.2000; 95: 3653–3661.
AbelE.A., SendagortaE., HoppeR.T.. Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides.J Am Acad Dermatol.1986; 14: 1029–1038.
83.
VonderheidE.C., TanE.T., KantorA.F.. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma.J Am Acad Dermatol.1989; 20: 416–428.
84.
RamsayD.L., HalperinP.S., Zeleniuch-JacquotteA.. Topical mechlorethamine therapy for early stage mycosis fungoides.J Am Acad Dermatol.1988; 19: 684–691.
85.
RamsayD.L., ParnesR.E., DubinN.. Response of mycosis fungoides to topical chemotherapy with mechlorethamine.Arch Dermatol.1984; 120: 1585–1590.
86.
PriceN.M., DeneauD.G., HoppeR.T.. The treatment of mycosis fungoides with ointment-based mechlorethamine.Arch Dermatol.1982; 118: 234–237.
CummingsJ., MacLellanA., LangdonS.J.. The long term stability of mechlorethamine hydrochloride (nitrogen mustard) ointment measured by HPLC.J Pharm Pharmacol.1993; 45: 6–9.
89.
ZackheimH.S.. Topical carmustine (BCNU) in the treatment of mycosis fungoides.Dermatol Ther.2003; 16: 299–302.
90.
DeethsM.J., ChapmanJ.T., DellavalleR.P.. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream.J Am Acad Dermatol.2005; 52: 275–280.
HonigsmannH., BrennerW., RauschmeierW.. Photochemotherapy for cutaneous T cell lymphoma. A follow-up study.J Am Acad Dermatol.1984; 10: 238–245.
93.
PowellF.C., SpiegelG.T., MullerS.A.. Treatment of parapsoriasis and mycosis fungoides: the role of psoralen and long-wave ultraviolet light A (PUVA).Mayo Clin Proc.1984; 59: 538–546.
94.
RosenbaumM.M., RoenigkH.H.Jr, CaroW.A.. Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques. Long-term follow-up in forty-three patients.J Am Acad Dermatol.1985; 13: 613–622.
95.
RoenigkH.H.Jr, KuzelT.M., SkoutelisA.P.. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.J Invest Dermatol.1990; 95(Suppl 6): 198S–205S.
96.
GuptaA.K., AndersonT.F.. Psoralen photochemotherapy.J Am Acad Dermatol.1987; 17: 703–734.
97.
MorisonW.L., MarwahaS., BeckL.. PUVA-induced phototoxicity: incidence and causes.J Am Acad Dermatol.1997; 36 (2 pt 1): 183–185.
98.
ThomsenK., HammarH., MolinL.. Retinoids plus PUVA (RePU-VA) and PUVA in mycosis fungoides, plaque stage. a report from the Scandinavian Mycosis Fungoides Group.Acta Derm Venereol.1989; 69: 536–538.
99.
HoppeR.T., CoxR.S., FuksZ.. Electron-beam therapy for mycosis fungoides: the Stanford University experience.Cancer Treat Rep.1979; 63: 691–700.
100.
HoppeR.T.. The management of mycosis fungoides at Stanford – standard and innovative treatment programmes.Leukemia.1991; 5(Suppl 1): 46–48.
101.
van VlotenW.A., de VroomeH., NoordijkE.M.. Total skin electron beam irradiation for cutaneous T-cell lymphoma (mycosis fungoides).Br J Dermatol.1985; 112: 697–702.
102.
LoT.C., SalzmanF.A., CosteyG.E.. Megavolt electron irradiation for localized mycosis fungoides.Acta Radiol Oncol.1981; 20: 71–74.
103.
EdelsonR., BergerC., GasparroF.. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results.N Engl J Med.1987; 316: 297–303.
104.
ArmusS., KeyesB., CahillC.. Photopheresis for the treatment of cutaneous T-cell lymphoma.J Am Acad Dermatol.1990; 23 (5 pt 1): 898–902.
105.
ZicJ., ArzubiagaC., SalhanyK.E.. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma.J Am Acad Dermatol.1992; 27 (5 pt 1): 729–736.
106.
HealdP., RookA., PerezM.. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy.J Am Acad Dermatol.1992; 27: 427–433.
107.
GottliebS.L., WolfeJ.T., FoxF.E.. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alpha: a 10-year experience at a single institution.J Am Acad Dermatol.1996; 35: 946–957.
108.
RingenbergQ.S., AndersonP.C.. Interferons in the treatment of skin disease.Int J Dermatol.1986; 25: 273–279.
109.
FoonK.A., BunnP.A.Jr. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia.Semin Oncol.1986; 13: 35–39.
110.
KohnE.C., SteisR.G., SausvilleE.A.. Phase II trial of intermittent high-dose recombinant interferon alpha-2a in mycosis fungoides and Sezary syndrome.J Clin Oncol.1990; 8: 155–160.
111.
BunnP.A.Jr, IhdeD.C., FoonK.A.. The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphomas.Cancer.1986; 57 (8 Suppl): 1689–1695.
112.
TalpurR., WardS., ApisarnthanaraxN.. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.J Am Acad Dermatol.2002; 47: 672–684.
113.
BrenemanD., DuvicM., KuzelT.. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.Arch Dermatol.2002; 138: 325–332.
114.
OlsenE., DuvicM., FrankelA.. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.J Clin Oncol.2001; 19: 376–388.
115.
FossF.M.. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.Ann N Y Acad Sci.2001; 941: 166–176.
116.
GorgunG., FossF.. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.Blood.2002; 100: 1399–1403.
117.
BunnP.A.Jr, HoffmanS.J., NorrisD.. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).Ann Intern Med.1994; 121: 592–602.
118.
DummerR., CozzioA., MeierS.. Standard and experimental therapy in cutaneous T-cell lymphomas.J Cutan Pathol.2006; 33(Suppl 1): 52–57.
119.
WollinaU., DummerR., BrockmeyerN.H.. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.Cancer.2003; 98: 993–1001.
120.
MarksP.A., RichonV.M., MillerT.. Histone deacetylase inhibitors.Adv Cancer Res.2004; 91: 137–168.
121.
LundinJ., HagbergH., ReppR.. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis dun-goides/Sezary syndrome.Blood.2003; 101: 4267–4272. Epub 2003 Jan 23.
122.
HagbergH., petterssonM., BjernerT.. Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4).Med Oncol.2005; 22: 191–194.
